Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11399697 | 0.77 | ALDH1A1 (0.47) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15360209 | 0.64 | LMNA (0.41) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL4793026 | 0.63 | RXFP1 (0.48) | MEN1KMT2AMAPTRXFP1KDM4E | |
| SCHEMBL2632919 | 0.62 | MEN1 (0.57) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2382218 | 0.62 | RXFP1 (0.47) | MEN1KMT2AMAPTRXFP1KDM4E | |
| SCHEMBL219172 | 0.59 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL1840979 | 0.58 | — | — | |
| SCHEMBL11401212 | 0.58 | NQO2 (0.35) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL8070172 | 0.57 | ALDH1A1 (0.41) | ALDH1A1GAAKMT2APOLBTSHR | |
| SCHEMBL23458980 | 0.57 | SMN1; SMN2 (0.42) | GAASMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150544-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2150544-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8063066-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063066-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063066-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-2150544-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2124/4885GAA 2762/4885SMN1; SMN2 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.